Top Dublin Biotech Companies (17)
Don't see your company?
Create a company profile
Through pioneering life science and artificial intelligence, we developed our unique Nuritas MagnifierNπΦ platform that allows us to identify, unlock, clinically test and patent peptides; turning them into powerful and precise ingredients that elevate natural efficacy. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat, to what we apply to our skin. By translating nature’s wisdom into innovation, together, we can change the life of billions.
Avectas is accelerating the future of cell therapy with a flexible, easy-to-integrate delivery platform that manufactures healthier and more functional cells for patients. Excelling at complex editing and challenging cargo delivery, the Avectas non-viral delivery platform ensures the next generation of cell therapies can be realized. The Solupore non-viral delivery system enables the next generation of cell therapies through unparalleled cell health and superior cell functionality, expanding the possibilities for complex editing and challenging cargo delivery. Easy to integrate into existing GMP processes, Solupore accelerates the translation of life-saving therapies to patients
We are driving the future of animal health through technology that enables the agriculture industry to target treatment based on rapid, on-site diagnostics. Helping maximise yield and reduce costs all whilst helping to reduce environmental impact
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Our Vision is to bring an Insect Farming revolution to the world, to end the overexploitation of land and ocean and to ultimately add to the progress of the human race. With revolutionary breeding and bio-conversion technologies, we maximise the extraction of high-value protein and oil products for the aquaculture, animal feed and plant nutrition industries. Our process produces no waste, lowers GHG emissions, optimises land usage, utilises industrial and agricultural waste streams and improves animal nutrition and health. We are ready to feed the world
We are a biotech longevity company on a mission to confront aging and age-related diseases. We’re building a coalition of the best scientists, physicians and investors to develop therapies and products that will help people experience better health for longer in their lives. We are organized to drive scientific innovation with speed and agility to market
Carrick Therapeutics is pioneering a portfolio of unique, first in class, cancer treatments that target driver mechanisms of the most aggressive forms of cancer, and which will be tailored to an individual patient’s tumour. Targeting the molecular pathways that drive the most aggressive and resistant forms of cancer will transform the way that cancer is treated and have a major impact on the lives of cancer patients. By linking a network of clinicians and scientists in internationally leading research institutes and hospitals, Carrick will streamline the introduction of these ground-breaking cancer therapies into the clinic, thus serving cancer patients around the world
Technology for sustainable and cost-effective conversion of biomass waste into clean and drop-in advanced fuels for the marine, road and aviation sectors. Fuel is produced efficiently, at low-cost and with currently 85% fewer GHGs than traditional fossil fuel production, and hard at work to achieve carbon-neutral and negative fuels. Highlights include; an operational pilot plant deployed in Spain, patented technology, exciting project economics and a commercial-scale project underway in the UK with global partners. Keywords: Renewables, Transportation, Carbon Neutral, Decarbonisation, Biofuels, Advanced Fuels, Road, Marine, Aviation, Drop-in Fuels, dRTFCs, Development Fuel, CleanTech
Prothena is a late-stage clinical biotechnology company with expertise in protein dysregulation and a diverse pipeline of novel investigational therapies for neurodegenerative and rare peripheral amyloid diseases. We are committed to developing novel and transformative medicines to create a better future for people in critical need of new treatment options. Our product portfolio is designed to make a significant impact on neurodegenerative and rare peripheral amyloid diseases, which affect millions of people and their families worldwide. We leverage insights around neurological dysfunction and the biology of misfolded proteins to develop novel therapeutic solutions that directly target pathogenic proteins in order to change the course of devastating diseases. At Prothena, our success is driven by our people. We are dedicated to attracting individuals who share our vision to improve human health by putting patients first. Our shared humanity drives a passionate and unwavering commitment to apply high scientific rigor toward developing innovative new therapies for patients. We have ambitious goals and take every aspect of our mission seriously, while enjoying the journey. Our values connect us – you will see and feel them come to life in all we do – together
Cellix is dedicated to providing our customers with easy-to-use benchtop instruments for cell analysis, cell sorting and customised solutions for microfluidics. Cellix was spun-out from Trinity College Dublin in 2006 when we launched our VenaFlux and Microfluidic Solutions ranges. Over the years, we have expanded our product offerings supporting our customers in several therapeutic areas including thrombosis, oncology, atherosclerosis, inflammation, infectious diseases, biofilm culture, stem cell research, sickle cell disease, asthma, and allergies. Our Microfluidic Solutions include set-ups for droplet generation, organ-on-chip and VOC analysis. More recently, Cellix's multi-disciplinary team of engineers and scientists have been developing our Inish Solutions range: microfluidic label-free impedance cell analysis and sorting. We want our customers to succeed so we are demystifying flow cytometry and bringing them simple, easy-to-use cell analysis and sorting for every lab, not just core facilities
Opsona Therapeutics is a leading drug development company specialising in the human immune system. Opsona is identifying new ways to prevent and treat autoimmune/inflammatory conditions, cancers and infectious diseases. Opsona's drug discovery & development is focused on the role of Toll-Like Receptors (TLRs) and Inflammasome signalling in human immunology. Since 2004, Opsona has also developed a unique and advanced pipeline of drugs. The company has research locations in Dublin (Ireland) and Lausanne (Switzerland)
Sublimity Therapeutics is a clinical-stage biotechnology company dedicated to identifying and developing meaningful new therapies for unmet clinical needs in gastrointestinal and immunological diseases. Led by a team of industry innovators and leveraging our Single-Multiple Pill (SmPill®) technology, we are advancing a diverse pipeline of oral small molecules that have the potential to make important contributions to human health. Our lead asset ST-0529 is currently being evaluated in the AURORA (CYC-202) Study, a Phase 2b clinical trial for moderate to severe Ulcerative Colitis
Through pioneering life science and artificial intelligence, we developed our unique Nuritas MagnifierNπΦ platform that allows us to identify, unlock, clinically test and patent peptides; turning them into powerful and precise ingredients that elevate natural efficacy. We want to empower people to live healthier lives, naturally by making our everyday products healthier, safer, greener and more efficacious. From what we eat, to what we apply to our skin. By translating nature’s wisdom into innovation, together, we can change the life of billions
Since our foundation in Dublin, Ireland in 1990, our mission has been to help our clients to accelerate the development of drugs and devices that save lives and improve quality of life. We do this by delivering best in class information, solutions and performance, with an unyielding focus on quality at all times. We offer a full range of consulting, development and commercialisation services from a global network of offices in 53 countries. We focus our innovation on the factors that are critical to our clients – reducing time to market, reducing cost, and increasing quality – and our global team of experts has extensive experience in a broad range of therapeutic areas.
Our purpose ensures that patients remain at the center of all we do. We live our purpose by sourcing the best science in the world; partnering with others in the healthcare system to improve access to our medicines; using digital technologies to enhance our drug discovery and development, as well as patient outcomes; and leading the conversation to advocate for pro-innovation/pro-patient policies.
Our commitment to The Science of Healthier Animals® guides our work. We offer our customers a range of technology solutions which fuse DNA and DATA intelligence to deliver unparalleled animal lifecycle knowledge and uniquely insightful connections. Together we can shape a better future for animal well-being and food trust
GH Research plc (NASDAQ: GHRS) is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders
Work Your Passion. Live Your Purpose.
